Sunovion Pharmaceuticals has announced Antony Loebel, MD, as its new president and chief executive officer, head of Clinical Development for Sumitomo Dainippon Pharma Group. The position will be effective from April 1, 2019.

Dr. Loebel joined the Company in 2007. His prior industry experience includes seven years in senior leadership roles at Pfizer and he has served as an executive leadership team member of Sunovion and an executive officer of Sumitomo Dainippon Pharma, the parent company of Sunovion.

“This is an exciting time for Sunovion to advance our research and innovation and build on our track record of providing important new treatment options,” said Dr. Loebel. “I am honoured to lead the dedicated employees of Sunovion who focus each day on serving and creating value for patients.”

He will succeed Nobuhiko Tamura, who has served as Sunovion’s executive leader since 2014.